Working… Menu

Treatment of Hepatitis C in Hemophilic Patients With HIV

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00055341
Recruitment Status : Completed
First Posted : February 27, 2003
Last Update Posted : July 30, 2008
Information provided by:
National Institute of Allergy and Infectious Diseases (NIAID)

Brief Summary:
Pegylated interferon (PEG-interferon) and ribavirin are accepted treatments for hepatitis C virus (HCV) infection. However, HCV infection progresses differently in patients who are coinfected with HIV and in hemophiliacs. This study will evaluate the effectiveness of PEG-interferon and ribavirin for treating HCV in HIV infected hemophiliacs.

Condition or disease Intervention/treatment Phase
HIV Infections Hepatitis C Hemophilia Drug: Peginterferon alfa-2a Drug: Ribavirin Phase 2

Detailed Description:

Hemophiliacs with symptomatic disease often receive blood products to correct clotting factor deficiencies. Prior to routine use of heat inactivation and screening of donor blood for specific viral pathogens, hemophiliacs were routinely exposed to, and infected with, viruses such as hepatitis B (HBV), HCV, and HIV. Studies in hemophiliacs suggest several important findings that warrant further investigation, including: 1) hemophiliacs infected with HCV may have more rapid progression to liver failure and death; 2) pooled blood concentrate from multiple donors leads to a high risk of mixed infection; and 3) different clinical outcomes and altered immune responses of HIV coinfected hemophiliacs may enhance understanding of mutant virus selection and the associated clinical outcomes. The purpose of this trial is to determine response rates to PEG-interferon and ribavirin in hemophiliacs with HCV alone and with HCV/HIV coinfection.

Participants in this study will be followed for 48 weeks on treatment and up to 36 months after treatment. Participants in this study will be admitted to the Clinical Research Center for 2 days at the beginning of the study. Participants will have 3 additional study visits in the first week of the study. After that, study visits occur at Weeks 2, 4, 8, 12, 16, 24, 32, 40, and 48. The follow-up visits will be at 4, 12, and 24 weeks following the end of treatment. Study visits include a physical exam and blood tests. Patients who do not respond to treatment will be followed in a prospective cohort study for up to 3 additional years so that evolution of the virus and associated immune responses can be evaluated.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 22 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective Multicenter, Phase II, Open Label, Controlled Trial Evaluating the Response of Hepatitis C Virus (HCV) to Pegylated Interferon Alpha-2A and Ribavirin in Hemophilic Patients With and Without Coinfection With the Human Immunodeficiency Virus (HIV)
Study Start Date : March 2002
Study Completion Date : June 2005

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   15 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Hemophilia A or B
  • Exposure to blood or blood products prior to 1987
  • Participating in "The Second Multicenter Hemophilia Cohort Study (MHCS-II)"
  • HCV reactive by second/third generation ELISA assay and/or RIBA
  • HCV RNA positive (PCR or bDNA methods)
  • Chronic hepatitis confirmed by liver biopsy within 6 months prior to study entry (Note: cirrhosis is not an exclusion factor)
  • HIV infection for coinfected group; HIV viral load of 10,000 copies/ml or less
  • If on antiretroviral drugs, stable regimen for at least 8 weeks prior to study entry
  • Acceptable methods of contraception

Exclusion Criteria

  • Hemoglobin less than 10 g/dl
  • For HIV coinfected group, CD4 count less than 200 cells/mm3 at time of screening visit
  • Previous interferon or ribavirin therapy
  • Corticosteroids or immunomodulatory drugs within 3 months prior to study entry
  • Hepatitis B (HBsAg reactive)
  • Alpha-1 antitrypsin deficiency
  • Wilson's disease
  • Hemochromatosis
  • Autoimmune disorder
  • Decompensated liver disease evidenced by encephalopathy, ascites, or variceal bleed
  • Prothrombin Time greater than 3 seconds above normal (International Normalized Ratio [INR] greater than 1.3)
  • Platelet count less than 90,000/microL
  • Active thyroid disease (thyroid replacement with normal TSH permitted)
  • Chronic renal insufficiency, defined as creatinine greater than 1.5 mg/dl
  • Life-threatening disease processes that could preclude completion of trial
  • Alcohol abuse that the local investigator feels would interfere with compliance
  • Illicit recreational drug use or methadone use within 6 months of study entry
  • Major depression with hospitalization or suicide attempt is a relative, but not absolute, contraindication to therapy based on timing, circumstances, and current stability as assessed by the investigator
  • Pregnant or breastfeeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00055341

Layout table for location information
United States, Ohio
University of Cincinnati
Cincinnati, Ohio, United States, 45267
Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Layout table for investigator information
Principal Investigator: Kenneth E. Sherman, MD, PhD University of Cincinnati

Publications of Results:
Layout table for additonal information Identifier: NCT00055341     History of Changes
Other Study ID Numbers: 1R01AI049508-01 ( U.S. NIH Grant/Contract )
5R01AI049508-02 ( U.S. NIH Grant/Contract )
First Posted: February 27, 2003    Key Record Dates
Last Update Posted: July 30, 2008
Last Verified: December 2006
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis A
Hepatitis C
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Peginterferon alfa-2a
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents